The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer
Several prostate-specific antigen (PSA) kinetics parameters such as nadir PSA level and time to nadir PSA level are used commonly as predictive prognostic factors for patients with metastatic prostate cancer (mPCa) who have undergone androgen deprivation therapy. However, based on the limitations of...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Kim, Ki Hong [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex - Siero, Jeroen C.W. ELSEVIER, 2014transfer abstract, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:33 ; year:2015 ; number:9 ; pages:38317-38322 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.urolonc.2015.04.007 |
|---|
| Katalog-ID: |
ELV029207789 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV029207789 | ||
| 003 | DE-627 | ||
| 005 | 20230623195756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.urolonc.2015.04.007 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015018000014.pica |
| 035 | |a (DE-627)ELV029207789 | ||
| 035 | |a (ELSEVIER)S1078-1439(15)00157-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Kim, Ki Hong |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer |
| 264 | 1 | |c 2015 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Several prostate-specific antigen (PSA) kinetics parameters such as nadir PSA level and time to nadir PSA level are used commonly as predictive prognostic factors for patients with metastatic prostate cancer (mPCa) who have undergone androgen deprivation therapy. However, based on the limitations of these factors, earlier and more clinically available prognostic factors are needed. Therefore, we examined the PSA half-life (PSAHL) estimated at the first follow-up visit as a prognostic factor of newly diagnosed mPCa. | ||
| 650 | 7 | |a Androgen deprivation therapy |2 Elsevier | |
| 650 | 7 | |a Prostate-specific antigen |2 Elsevier | |
| 650 | 7 | |a Metastasis |2 Elsevier | |
| 650 | 7 | |a Prostate cancer |2 Elsevier | |
| 700 | 1 | |a Han, Kyung Seok |4 oth | |
| 700 | 1 | |a Kim, Kwang Hyun |4 oth | |
| 700 | 1 | |a Kim, Dae Keun |4 oth | |
| 700 | 1 | |a Koo, Kyo Chul |4 oth | |
| 700 | 1 | |a Rha, Koon Ho |4 oth | |
| 700 | 1 | |a Choi, Young Deuk |4 oth | |
| 700 | 1 | |a Hong, Sung Joon |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Siero, Jeroen C.W. ELSEVIER |t BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |d 2014transfer abstract |g Amsterdam [u.a.] |w (DE-627)ELV012523860 |
| 773 | 1 | 8 | |g volume:33 |g year:2015 |g number:9 |g pages:38317-38322 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.urolonc.2015.04.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2015 |e 9 |h 38317-38322 |g 6 |y 33.2015, 9, 383.e17-, (6 S.) | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
k h k kh khk |
|---|---|
| matchkey_str |
kimkihonghankyungseokkimkwanghyunkimdaek:2015----:hponsiefcopottseiiatgnafiethfrtolwpiiinwyi |
| hierarchy_sort_str |
2015 |
| publishDate |
2015 |
| allfields |
10.1016/j.urolonc.2015.04.007 doi GBVA2015018000014.pica (DE-627)ELV029207789 (ELSEVIER)S1078-1439(15)00157-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Kim, Ki Hong verfasserin aut The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Several prostate-specific antigen (PSA) kinetics parameters such as nadir PSA level and time to nadir PSA level are used commonly as predictive prognostic factors for patients with metastatic prostate cancer (mPCa) who have undergone androgen deprivation therapy. However, based on the limitations of these factors, earlier and more clinically available prognostic factors are needed. Therefore, we examined the PSA half-life (PSAHL) estimated at the first follow-up visit as a prognostic factor of newly diagnosed mPCa. Androgen deprivation therapy Elsevier Prostate-specific antigen Elsevier Metastasis Elsevier Prostate cancer Elsevier Han, Kyung Seok oth Kim, Kwang Hyun oth Kim, Dae Keun oth Koo, Kyo Chul oth Rha, Koon Ho oth Choi, Young Deuk oth Hong, Sung Joon oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:33 year:2015 number:9 pages:38317-38322 extent:6 https://doi.org/10.1016/j.urolonc.2015.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 33 2015 9 38317-38322 6 33.2015, 9, 383.e17-, (6 S.) 045F 610 |
| spelling |
10.1016/j.urolonc.2015.04.007 doi GBVA2015018000014.pica (DE-627)ELV029207789 (ELSEVIER)S1078-1439(15)00157-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Kim, Ki Hong verfasserin aut The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Several prostate-specific antigen (PSA) kinetics parameters such as nadir PSA level and time to nadir PSA level are used commonly as predictive prognostic factors for patients with metastatic prostate cancer (mPCa) who have undergone androgen deprivation therapy. However, based on the limitations of these factors, earlier and more clinically available prognostic factors are needed. Therefore, we examined the PSA half-life (PSAHL) estimated at the first follow-up visit as a prognostic factor of newly diagnosed mPCa. Androgen deprivation therapy Elsevier Prostate-specific antigen Elsevier Metastasis Elsevier Prostate cancer Elsevier Han, Kyung Seok oth Kim, Kwang Hyun oth Kim, Dae Keun oth Koo, Kyo Chul oth Rha, Koon Ho oth Choi, Young Deuk oth Hong, Sung Joon oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:33 year:2015 number:9 pages:38317-38322 extent:6 https://doi.org/10.1016/j.urolonc.2015.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 33 2015 9 38317-38322 6 33.2015, 9, 383.e17-, (6 S.) 045F 610 |
| allfields_unstemmed |
10.1016/j.urolonc.2015.04.007 doi GBVA2015018000014.pica (DE-627)ELV029207789 (ELSEVIER)S1078-1439(15)00157-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Kim, Ki Hong verfasserin aut The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Several prostate-specific antigen (PSA) kinetics parameters such as nadir PSA level and time to nadir PSA level are used commonly as predictive prognostic factors for patients with metastatic prostate cancer (mPCa) who have undergone androgen deprivation therapy. However, based on the limitations of these factors, earlier and more clinically available prognostic factors are needed. Therefore, we examined the PSA half-life (PSAHL) estimated at the first follow-up visit as a prognostic factor of newly diagnosed mPCa. Androgen deprivation therapy Elsevier Prostate-specific antigen Elsevier Metastasis Elsevier Prostate cancer Elsevier Han, Kyung Seok oth Kim, Kwang Hyun oth Kim, Dae Keun oth Koo, Kyo Chul oth Rha, Koon Ho oth Choi, Young Deuk oth Hong, Sung Joon oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:33 year:2015 number:9 pages:38317-38322 extent:6 https://doi.org/10.1016/j.urolonc.2015.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 33 2015 9 38317-38322 6 33.2015, 9, 383.e17-, (6 S.) 045F 610 |
| allfieldsGer |
10.1016/j.urolonc.2015.04.007 doi GBVA2015018000014.pica (DE-627)ELV029207789 (ELSEVIER)S1078-1439(15)00157-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Kim, Ki Hong verfasserin aut The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Several prostate-specific antigen (PSA) kinetics parameters such as nadir PSA level and time to nadir PSA level are used commonly as predictive prognostic factors for patients with metastatic prostate cancer (mPCa) who have undergone androgen deprivation therapy. However, based on the limitations of these factors, earlier and more clinically available prognostic factors are needed. Therefore, we examined the PSA half-life (PSAHL) estimated at the first follow-up visit as a prognostic factor of newly diagnosed mPCa. Androgen deprivation therapy Elsevier Prostate-specific antigen Elsevier Metastasis Elsevier Prostate cancer Elsevier Han, Kyung Seok oth Kim, Kwang Hyun oth Kim, Dae Keun oth Koo, Kyo Chul oth Rha, Koon Ho oth Choi, Young Deuk oth Hong, Sung Joon oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:33 year:2015 number:9 pages:38317-38322 extent:6 https://doi.org/10.1016/j.urolonc.2015.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 33 2015 9 38317-38322 6 33.2015, 9, 383.e17-, (6 S.) 045F 610 |
| allfieldsSound |
10.1016/j.urolonc.2015.04.007 doi GBVA2015018000014.pica (DE-627)ELV029207789 (ELSEVIER)S1078-1439(15)00157-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Kim, Ki Hong verfasserin aut The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer 2015 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Several prostate-specific antigen (PSA) kinetics parameters such as nadir PSA level and time to nadir PSA level are used commonly as predictive prognostic factors for patients with metastatic prostate cancer (mPCa) who have undergone androgen deprivation therapy. However, based on the limitations of these factors, earlier and more clinically available prognostic factors are needed. Therefore, we examined the PSA half-life (PSAHL) estimated at the first follow-up visit as a prognostic factor of newly diagnosed mPCa. Androgen deprivation therapy Elsevier Prostate-specific antigen Elsevier Metastasis Elsevier Prostate cancer Elsevier Han, Kyung Seok oth Kim, Kwang Hyun oth Kim, Dae Keun oth Koo, Kyo Chul oth Rha, Koon Ho oth Choi, Young Deuk oth Hong, Sung Joon oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:33 year:2015 number:9 pages:38317-38322 extent:6 https://doi.org/10.1016/j.urolonc.2015.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 33 2015 9 38317-38322 6 33.2015, 9, 383.e17-, (6 S.) 045F 610 |
| language |
English |
| source |
Enthalten in BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex Amsterdam [u.a.] volume:33 year:2015 number:9 pages:38317-38322 extent:6 |
| sourceStr |
Enthalten in BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex Amsterdam [u.a.] volume:33 year:2015 number:9 pages:38317-38322 extent:6 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Androgen deprivation therapy Prostate-specific antigen Metastasis Prostate cancer |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
| authorswithroles_txt_mv |
Kim, Ki Hong @@aut@@ Han, Kyung Seok @@oth@@ Kim, Kwang Hyun @@oth@@ Kim, Dae Keun @@oth@@ Koo, Kyo Chul @@oth@@ Rha, Koon Ho @@oth@@ Choi, Young Deuk @@oth@@ Hong, Sung Joon @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV012523860 |
| dewey-sort |
3610 |
| id |
ELV029207789 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029207789</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623195756.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.urolonc.2015.04.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015018000014.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029207789</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1078-1439(15)00157-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kim, Ki Hong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Several prostate-specific antigen (PSA) kinetics parameters such as nadir PSA level and time to nadir PSA level are used commonly as predictive prognostic factors for patients with metastatic prostate cancer (mPCa) who have undergone androgen deprivation therapy. However, based on the limitations of these factors, earlier and more clinically available prognostic factors are needed. Therefore, we examined the PSA half-life (PSAHL) estimated at the first follow-up visit as a prognostic factor of newly diagnosed mPCa.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Androgen deprivation therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate-specific antigen</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Metastasis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Han, Kyung Seok</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kim, Kwang Hyun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kim, Dae Keun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Koo, Kyo Chul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rha, Koon Ho</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Choi, Young Deuk</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hong, Sung Joon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Siero, Jeroen C.W. ELSEVIER</subfield><subfield code="t">BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012523860</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:33</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:9</subfield><subfield code="g">pages:38317-38322</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.urolonc.2015.04.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">33</subfield><subfield code="j">2015</subfield><subfield code="e">9</subfield><subfield code="h">38317-38322</subfield><subfield code="g">6</subfield><subfield code="y">33.2015, 9, 383.e17-, (6 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Kim, Ki Hong |
| spellingShingle |
Kim, Ki Hong ddc 610 Elsevier Androgen deprivation therapy Elsevier Prostate-specific antigen Elsevier Metastasis Elsevier Prostate cancer The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer |
| authorStr |
Kim, Ki Hong |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV012523860 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer Androgen deprivation therapy Elsevier Prostate-specific antigen Elsevier Metastasis Elsevier Prostate cancer Elsevier |
| topic |
ddc 610 Elsevier Androgen deprivation therapy Elsevier Prostate-specific antigen Elsevier Metastasis Elsevier Prostate cancer |
| topic_unstemmed |
ddc 610 Elsevier Androgen deprivation therapy Elsevier Prostate-specific antigen Elsevier Metastasis Elsevier Prostate cancer |
| topic_browse |
ddc 610 Elsevier Androgen deprivation therapy Elsevier Prostate-specific antigen Elsevier Metastasis Elsevier Prostate cancer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
k s h ks ksh k h k kh khk d k k dk dkk k c k kc kck k h r kh khr y d c yd ydc s j h sj sjh |
| hierarchy_parent_title |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
| hierarchy_parent_id |
ELV012523860 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV012523860 |
| title |
The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer |
| ctrlnum |
(DE-627)ELV029207789 (ELSEVIER)S1078-1439(15)00157-X |
| title_full |
The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer |
| author_sort |
Kim, Ki Hong |
| journal |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
| journalStr |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
38317 |
| author_browse |
Kim, Ki Hong |
| container_volume |
33 |
| physical |
6 |
| class |
610 610 DE-600 610 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Kim, Ki Hong |
| doi_str_mv |
10.1016/j.urolonc.2015.04.007 |
| dewey-full |
610 |
| title_sort |
prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer |
| title_auth |
The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer |
| abstract |
Several prostate-specific antigen (PSA) kinetics parameters such as nadir PSA level and time to nadir PSA level are used commonly as predictive prognostic factors for patients with metastatic prostate cancer (mPCa) who have undergone androgen deprivation therapy. However, based on the limitations of these factors, earlier and more clinically available prognostic factors are needed. Therefore, we examined the PSA half-life (PSAHL) estimated at the first follow-up visit as a prognostic factor of newly diagnosed mPCa. |
| abstractGer |
Several prostate-specific antigen (PSA) kinetics parameters such as nadir PSA level and time to nadir PSA level are used commonly as predictive prognostic factors for patients with metastatic prostate cancer (mPCa) who have undergone androgen deprivation therapy. However, based on the limitations of these factors, earlier and more clinically available prognostic factors are needed. Therefore, we examined the PSA half-life (PSAHL) estimated at the first follow-up visit as a prognostic factor of newly diagnosed mPCa. |
| abstract_unstemmed |
Several prostate-specific antigen (PSA) kinetics parameters such as nadir PSA level and time to nadir PSA level are used commonly as predictive prognostic factors for patients with metastatic prostate cancer (mPCa) who have undergone androgen deprivation therapy. However, based on the limitations of these factors, earlier and more clinically available prognostic factors are needed. Therefore, we examined the PSA half-life (PSAHL) estimated at the first follow-up visit as a prognostic factor of newly diagnosed mPCa. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
9 |
| title_short |
The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer |
| url |
https://doi.org/10.1016/j.urolonc.2015.04.007 |
| remote_bool |
true |
| author2 |
Han, Kyung Seok Kim, Kwang Hyun Kim, Dae Keun Koo, Kyo Chul Rha, Koon Ho Choi, Young Deuk Hong, Sung Joon |
| author2Str |
Han, Kyung Seok Kim, Kwang Hyun Kim, Dae Keun Koo, Kyo Chul Rha, Koon Ho Choi, Young Deuk Hong, Sung Joon |
| ppnlink |
ELV012523860 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.urolonc.2015.04.007 |
| up_date |
2024-07-06T20:50:29.968Z |
| _version_ |
1803864275647725568 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029207789</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623195756.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.urolonc.2015.04.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015018000014.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029207789</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1078-1439(15)00157-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kim, Ki Hong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Several prostate-specific antigen (PSA) kinetics parameters such as nadir PSA level and time to nadir PSA level are used commonly as predictive prognostic factors for patients with metastatic prostate cancer (mPCa) who have undergone androgen deprivation therapy. However, based on the limitations of these factors, earlier and more clinically available prognostic factors are needed. Therefore, we examined the PSA half-life (PSAHL) estimated at the first follow-up visit as a prognostic factor of newly diagnosed mPCa.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Androgen deprivation therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate-specific antigen</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Metastasis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Han, Kyung Seok</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kim, Kwang Hyun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kim, Dae Keun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Koo, Kyo Chul</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rha, Koon Ho</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Choi, Young Deuk</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hong, Sung Joon</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Siero, Jeroen C.W. ELSEVIER</subfield><subfield code="t">BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012523860</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:33</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:9</subfield><subfield code="g">pages:38317-38322</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.urolonc.2015.04.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">33</subfield><subfield code="j">2015</subfield><subfield code="e">9</subfield><subfield code="h">38317-38322</subfield><subfield code="g">6</subfield><subfield code="y">33.2015, 9, 383.e17-, (6 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4008236 |